Michael is a successful biopharmaceutical entrepreneur, operating executive and investor. He has founded or co-founded multiple biopharmaceutical companies and has a passion for developing and commercializing innovative products that can make a major impact on the lives of patients globally.
Michael is a Founder of PaxMedica and serves as the Company’s Executive Chairman. He is also the Founder and Managing Partner of TardiMed Sciences, a life sciences investment and company creation firm. In 2015, he co-founded Castle Creek Pharmaceuticals which, under his leadership, raised more than $120 million and was built into a late clinical stage company developing important therapies for patients with rare dermatologic conditions. Prior to Castle Creek, Michael founded Norphan Pharmaceuticals, which developed drugs for patients with rare neurologic diseases, including one of the first drugs to gain FDA approval for the treatment of Duchenne muscular dystrophy. Earlier in his career, Michael was a venture capitalist and operating executive, holding key commercial roles at Merck & Co. and Forest Laboratories. Michael holds advanced degrees in business and science, with an MBA from New York University’s Stern School of Business, an MS in Neuroscience from the University of Rochester, and a BS, with honors, from Johns Hopkins University.